Video

Early Promise of Radiation Plus PCV in Patients With Low-Grade Glioma

Author(s):

Erica Bell, PhD
Conference|ASCO Annual Meeting

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Erica Bell, PhD, assistant professor-Clinical, Ohio State University Comprehensive Cancer Center, discusses a mutational analysis examining radiation therapy plus procarbazine, CCNU, and vincristine (PCV) as a potential treatment for patients with high-risk, low-grade glioma.

Related Videos
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego
Julia Foldi, MD, PhD
Joaquim Bellmunt, MD, PhD
Brandon Huffman, MD
Sattva S. Neelapu, MD
Related Content
Allison Graeter, MD
June 12th 2024

Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment
May 10th 2021

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

Lakshmi Nayak, MD, director, Center for CNS Lymphoma, Dana-Farber Cancer Institute; associate professor, neurology, Harvard Medical School
June 11th 2024

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Craig E. Devoe, MD, MS
June 11th 2024

Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC

Michael J. Morris, MD
June 10th 2024

JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise

Daniel P. Petrylak, MD, of Yale School of Medicine
June 10th 2024

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC